The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Tekmar hires former Kromek CFO; Redx chair departs

Tue, 01st Jun 2021 15:51

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

Tekmar Group PLC - provider of technology and services for offshore energy markets - Hires Derek Bulmer as new chief financial officer. Sue Hurst, the current CFO, steps down from the role on Tuesday but will remain on the board for a transition period. Bulmer was CFO and in-house counsel for AIM-listed radiation detection technology firm Kromek Group PLC from 2010 until last year. Prior to Kromek, he had worked at brick maker Ibstock PLC, among other employers. Tekmar also announced its annual results on Tuesday. For the 12 months ended March 31, it swung to pretax loss of GBP2.5 million from a profit of GBP2.0 million the year before, on revenue which declined 29% to GBP29.1 million from GBP40.9 million.

----------

Redx Pharma PLC - Macclesfield, England-based discovery of treatments for cancer and fibrotic disease - Chair Iain Ross steps down as a director immediately "to pursue other business opportunities". Redx makes Independent Non-Executive Director Peter Presland the interim chair as it starts search for new chair. "Iain has been the lynchpin in the turnaround of Redx, and we are very grateful for his innumerable contributions as chairman over the last four years," says Chief Executive Officer Lisa Anson. Ross says he remains "a supportive shareholder".

----------

Chamberlin PLC - West Midlands-based castings and engineering - New CEO Kevin Price and new Finance Director Alan Tomlinson join the board on Tuesday. Non-Executive Director Trevor Brown moves to executive director, responsible for company strategy, effective immediately, while David Flowerday resigns as non-executive director from Monday.

----------

Challenger Energy Group PLC - assets in Bahamas, Uruguay, Trinidad & Tobago and Suriname, previously known as Bahamas Petroleum Co PLC - Eytan Uliel formally takes up role as CEO. Simon Potter steps down as CEO but remains as non-executive director. Stephen Bizzell joins board as non-executive director, replacing Ross McDonald.

----------

Longboat Energy PLC - North Sea-focused exploration and production - Hires Nick Ingrassia as corporate development director. Ingrassia had joined Longboat back in September. Among other roles, he had worked at Faroe Petroleum PLC, whose former management team are behind Longboat Energy. Ingrassia's appointment comes alongside Longboat's announcement on Tuesday of three acquisitions to develop an exploration drilling programme on the Norwegian continental shelf. The acquisitions will be accompanied by a GBP35 million equity raise and are classified as a reverse takeover of Longboat under AIM rules.

----------

Trustpilot AS - Copenhagen-based online consumer reviews platform - Hires Joe Hurd as independent non-executive director. California-based Hurd is an independent public board director and adviser.

----------

India Capital Growth Fund Ltd - invests directly, or indirectly, in companies based in India - Hires Lynne Duquemin as non-executive director, effective immediately, as successor to Peter Niven, who will retire from the board at the end of 2021. Duquemin is a Guernsey resident with "deep experience of investment management and advisory services".

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
10 Jul 2019 10:40

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus down

Read more
10 Jul 2019 09:41

Redx Pharma Shares Double After Jazz Pharmaceutical Deal

(Alliance News) - Redx Pharma PLC said Wednesday it has signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals PLC to sell its pan-RAF inhibitor programme.Shares in the and a

Read more
10 Jun 2019 10:10

Redx Pharma Gets GBP2.5 Million Financing As Interim Loss Narrows

LONDON (Alliance News) - Redx Pharma PLC on Monday said its loss narrowed in the first half of its current financial year as it progresses on cancer and idiopathic pulmonary fibrosis drugs the and

Read more
10 Jun 2019 08:29

Redx Pharma narrows losses as RXC004 trials recommence

(Sharecast News) - Drug discovery and development company Redx Pharma published its interim results on Monday, revealing it had narrowed first-half losses as it progresses on cancer and idiopathic pulmonary fibrosis drugs development.

Read more
3 May 2019 14:07

Redx Pharma Exploring New Financing Options Despite Progress

LONDON (Alliance News) - Cancer and fibrosis-focused drug firm Redx Pharma PLC is "greatly encouraged" by talks over securing new financing.In November, Redx said it was looking a

Read more
3 May 2019 11:17

Redx Pharma extends cash runway into July

(Sharecast News) - Drug discovery and development company Redx Pharma updated the market on its ongoing plans to strengthen its balance sheet on Friday, with its board reiterating its commitment to strengthening the balance sheet in order to extend the cash runway beyond the second quarter of 2019, as it initially announced in November.

Read more
12 Feb 2019 13:42

Redx Pharma reveals promising data on 'ROCK2' compound

(Sharecast News) - Drug discovery and development company Redx Pharma announced promising preclinical efficacy data for its lead selective 'ROCK2' compound on Tuesday.

Read more
12 Feb 2019 09:45

Redx Pharma Sees Promising Results From Liver Disease Treatment

LONDON (Alliance News) - Redx Pharma PLC said Tuesday that preclinical efficacy data for its ROCK2 compound showed the product was able to have an impact on established fibrosis.Shares in a

Read more
6 Feb 2019 11:45

Redx Pharma Receives Oustanding Loan Amounts From Redag

LONDON (Alliance News) - Redx Pharma PLC on Wednesday said that it received a full cash repayment of GBP869,126, representing the outstanding amount of a loan made in 2014 to Redag Crop Protection

Read more
31 Jan 2019 11:03

Deinove Backs Out Of Anti-Infective NBTI Programme With Redx Pharma

LONDON (Alliance News) - Redx Pharma PLC on Thursday said French biotech firm Deinove SA will not exercise its option for Redx's novel bacterial topoisomerase inhibitor programme.Shares

Read more
31 Jan 2019 09:45

Deinove hands rights to NBTI programme back to Redx Pharma

(Sharecast News) - Drug discovery and development company Redx Pharma announced on Thursday that Deinove had decided not to exercise its option for Redx's 'Novel Bacterial Topoisomerase Inhibitor' (NBTI) programme.

Read more
30 Nov 2018 10:36

Redx Pharma Drug Candidate RXC006 To Be Developed As Fibrosis Drug

LONDON (Alliance News) - Drug developer Redx Pharma PLC said Friday its RXC006 drug candidate was able to suppress lung fibrosis in living organisms and will be developed as a treatment for in up

Read more
30 Nov 2018 10:31

Redx Pharma jumps as first data shows 'great potential' for fibrosis candidate

(Sharecast News) - Redx Pharma made gains on Friday after it said that pre-clinical data suggested that its RXC006 drug candidate has "great potential" as a treatment for fibrosis.

Read more
19 Nov 2018 13:07

Redx Pharma Posts Large Annual Loss, Appoints Astra Executive As CFO

LONDON (Alliance News) - Redx Pharma PLC on Monday posted a large loss due to the absence of a big exceptional disposal gain seen a year before and said that it has appointed James Mead as its new

Read more
19 Nov 2018 08:59

Redx Pharma swings to a loss following 'seminal' year

(Sharecast News) - A year after clambering out of administration, drug discovery and development outfit Redx Pharma swung to a loss but remains confident of making progress with a drug pipeline refocused on cancer and fibrosis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.